BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-6834 [PMID: 26078558 DOI: 10.3748/wjg.v21.i22.6820]
URL: https://www.wjgnet.com/1948-5182/full/v21/i22/6820.htm
Number Citing Articles
1
Frank Tacke. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosisExpert Opinion on Investigational Drugs 2018; 27(3): 301 doi: 10.1080/13543784.2018.1442436
2
Qian Li, Manish Dhyani, Joseph R Grajo, Claude Sirlin, Anthony E Samir. Current status of imaging in nonalcoholic fatty liver diseaseWorld Journal of Hepatology 2018; 10(8): 530-542 doi: 10.4254/wjh.v10.i8.530
3
Eider Talavera-Urquijo, Sarai Rodríguez-Navarro, Marc Beisani, Maria Teresa Salcedo-Allende, Aisha Chakkur, Marc Arús-Avilés, Manel Cremades, Salvador Augustin, María Martell, José M. Balibrea. Morphofunctional Changes After Sleeve Gastrectomy and Very Low Calorie Diet in an Animal Model of Non-Alcoholic Fatty Liver DiseaseObesity Surgery 2018; 28(1): 142 doi: 10.1007/s11695-017-2805-4
4
Giuseppe Dattilo, Francesco Borgia, Claudio Guarneri, Matteo Casale, Roberto Bitto, Claudia Morabito, Salvatore Signorelli, Niki Katsiki, Serafinello P. Cannavò. Cardiovascular Risk in Psoriasis: Current State of the ArtCurrent Vascular Pharmacology 2018; 17(1): 85 doi: 10.2174/1570161115666171116163816
5
Alex Benjamin, Rebecca Zubajlo, Kai Thomenius, Manish Dhyani, Kanakaraju Kaliannan, Anthony E. Samir, Brian W. Anthony. Non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) using ultrasound image echogenicity2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2017; : 2920 doi: 10.1109/EMBC.2017.8037468
6
Niki Katsiki, Athanasios D Giannoukas, Vasilios G Athyros, Dimitri P Mikhailidis. Lipid-lowering treatment in peripheral artery diseaseCurrent Opinion in Pharmacology 2018; 39: 19 doi: 10.1016/j.coph.2018.01.003
7
Evangelos Chartampilas. Imaging of nonalcoholic fatty liver disease and its clinical utilityHormones 2018; 17(1): 69 doi: 10.1007/s42000-018-0012-x
8
I. V. Logacheva, T. A. Ryazanova, S. B. Ponomarev, V. R. Makarova. Multivariate prognosis of non-alcoholic fatty liver disease development in visceral obesity in patients with coronary artery disease and hypertensionRussian Journal of Cardiology 2021; 26(1): 4015 doi: 10.15829/1560-4071-2021-4015
9
Vasilios G. Athyros, Dimitri P. Mikhailidis. High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practiceJournal of Diabetes and its Complications 2016; 30(1): 9 doi: 10.1016/j.jdiacomp.2015.07.012
10
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Anastasia Skalkou, Ioanna Zografou, Vasilios G. Athyros. The potential role of statins in treating liver diseaseExpert Review of Gastroenterology & Hepatology 2018; 12(4): 331 doi: 10.1080/17474124.2018.1439379
11
Adriana Sánchez-García, Amirhossein Sahebkar, Mario Simental-Mendía, Luis E. Simental-Mendía. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trialsPharmacological Research 2018; 135: 144 doi: 10.1016/j.phrs.2018.08.008
12
I. V. Logacheva, T. A. Ryazanova, V. R. Makarova, O. V. Surnina. Non-Alcoholic Fatty Liver Disease in Cardiac Patients with Overweight and ObesityRussian Journal of Gastroenterology, Hepatology, Coloproctology 2019; 28(6): 27 doi: 10.22416/1382-4376-2018-28-6-27-37
13
Niki Katsiki, Anca Pantea Stoian, Paschalis Steiropoulos, Nikolaos Papanas, Andra-Iulia Suceveanu, Dimitri P. Mikhailidis. Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An OverviewMetabolites 2020; 10(11): 465 doi: 10.3390/metabo10110465
14
M. Papagianni, K. Tziomalos. Non-alcoholic fatty liver disease: an emerging predictor of stroke risk, severity and outcomeEuropean Journal of Neurology 2018; 25(4): 610 doi: 10.1111/ene.13584
15
Vasilios G. Athyros, Stergios A. Polyzos, Jiannis Kountouras, Niki Katsiki, Panagiotis Anagnostis, Michael Doumas, Christos S. Mantzoros. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the BlockCurrent Vascular Pharmacology 2020; 18(2): 172 doi: 10.2174/1570161117666190405164313
16
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis, Dimitri P. Mikhailidis. Statins and non-alcoholic steatohepatitisJournal of Hepatology 2016; 64(1): 241 doi: 10.1016/j.jhep.2015.09.021
17
Simona Panunzi, Sabina Maltese, Ornella Verrastro, Luca Labbate, Andrea De Gaetano, Maurizio Pompili, Esmeralda Capristo, Stefan R. Bornstein, Geltrude Mingrone. Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysisDiabetes, Obesity and Metabolism 2021; 23(4): 980 doi: 10.1111/dom.14304
18
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An updateMetabolism 2016; 65(8): 1109 doi: 10.1016/j.metabol.2016.05.003
19
Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis. Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. Curr Med Res Opin 2017;33:797-801Current Medical Research and Opinion 2017; 33(12): 2261 doi: 10.1080/03007995.2017.1333955
20
Hadi Emamat, Hossein Farhadnejad, Hossein Poustchi, Azita Hekmatdoost. Galactose intake is related to nonalcoholic fatty liver diseaseNutrition & Food Science 2019; 49(3): 359 doi: 10.1108/NFS-06-2018-0174
21
Manorama Swain, Preetam Nath, Prasant Kumar Parida, Jimmy Narayan, Pradeep Kumar Padhi, Girish Kumar Pati, Ayaskanta Singh, Bijay Misra, Debasis Misra, Sanjib Kumar Kar, Manas Kumar Panigrahi, Chudamani Meher, Omprakash Agrawal, Niranjan Rout, Kaumudee Pattnaik, Pallavi Bhuyan, Pramila Kumari Mishra, Shivaram Prasad Singh. Biochemical Profile of Nonalcoholic Fatty Liver Disease Patients in Eastern India with Histopathological CorrelationIndian Journal of Clinical Biochemistry 2017; 32(3): 306 doi: 10.1007/s12291-016-0612-7
22
Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?Metabolism 2019; 98: iii doi: 10.1016/j.metabol.2019.07.009
23
Simona Cernea, Avivit Cahn, Itamar Raz. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetesExpert Review of Clinical Pharmacology 2017; 10(5): 535 doi: 10.1080/17512433.2017.1300059
24
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?American Journal of Physiology-Gastrointestinal and Liver Physiology 2017; 312(6): G681 doi: 10.1152/ajpgi.00101.2017
25
Niki Katsiki, Dimitrios Tousoulis. Diabetes mellitus and comorbidities: A bad romanceHellenic Journal of Cardiology 2020; 61(1): 23 doi: 10.1016/j.hjc.2020.02.009
26
Liat Mlynarsky, Dalit Schlesinger, Roni Lotan, Muriel Webb, Zamir Halpern, Erwin Santo, Oren Shibolet, Shira Zelber-Sagi. Non-alcoholic fatty liver disease is not associated with a lower health perceptionWorld Journal of Gastroenterology 2016; 22(17): 4362-4372 doi: 10.3748/wjg.v22.i17.4362
27
Derek M. Erion, Hyun-Jun Park, Hui-Young Lee. The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbiditiesBMB Reports 2016; 49(3): 139 doi: 10.5483/BMBRep.2016.49.3.268
28
Takashi Kato, Man Hagiyama, Yasutoshi Takashima, Azusa Yoneshige, Akihiko Ito. Cell adhesion molecule-1 shedding induces apoptosis of renal epithelial cells and exacerbates human nephropathiesAmerican Journal of Physiology-Renal Physiology 2018; 314(3): F388 doi: 10.1152/ajprenal.00385.2017
29
Kalliopi Pafili, Efstratios Maltezos, Nikolaos Papanas. Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?Expert Opinion on Pharmacotherapy 2018; 19(3): 185 doi: 10.1080/14656566.2017.1413346
30
Rebecca E. Zubajlo, Alex Benjamin, Joseph R. Grajo, Kanakaraju Kaliannan, Jing X. Kang, Atul K. Bhan, Kai E. Thomenius, Brian W. Anthony, Manish Dhyani, Anthony E. Samir. Experimental Validation of Longitudinal Speed of Sound Estimates in the Diagnosis of Hepatic Steatosis (Part II)Ultrasound in Medicine & Biology 2018; 44(12): 2749 doi: 10.1016/j.ultrasmedbio.2018.07.020
31
A. Yu. Timakova, Yu. P. Skirdenko, M. A. Livzan, T. S. Krolevets, N. A. Nikolaev, A. V. Nelidova. Cardiovascular comorbidity in non-alcoholic fatty liver diseaseExperimental and Clinical Gastroenterology 2020; (10): 88 doi: 10.31146/1682-8658-ecg-182-10-88-95
32
Arrigo F. G. Cicero, Alessandro Colletti. An update on the safety of nutraceuticals and effects on lipid parametersExpert Opinion on Drug Safety 2018; 17(3): 303 doi: 10.1080/14740338.2018.1429404
33
T. D. Filippatos, K. Alexakis, V. Mavrikaki, D. P. Mikhailidis. Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, “Prediabetes,” Diabetes and AtherosclerosisDigestive Diseases and Sciences 2022; 67(1): 26 doi: 10.1007/s10620-021-06824-7
34
Jie Han, Yong Wang, Zhongshang Yuan, Lu Liu, Meng Zhao, Qingbo Guan, Haiqing Zhang, Qiu Li, Jin Xu, Ling Gao, Jiajun Zhao, Xu Zhang. Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosisMedicine 2019; 98(11): e14896 doi: 10.1097/MD.0000000000014896
35
Munehisa Bekki, Nobuhiro Tahara, Atsuko Tahara, Sachiyo Igata, Akihiro Honda, Yoichi Sugiyama, Tomohisa Nakamura, Jiahui Sun, Yuki Kumashiro, Takanori Matsui, Yoshihiro Fukumoto, Sho-ichi Yamagishi. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot StudyCurrent Vascular Pharmacology 2019; 17(4): 411 doi: 10.2174/1570161116666180515154555
36
Tomas Vita, David J. Murphy, Michael T. Osborne, Navkaranbir S. Bajaj, Abhishek Keraliya, Sophia Jacob, Angel Joel Diaz Martinez, Ariana Nodoushani, Paco Bravo, Jon Hainer, Courtney F. Bibbo, Michael L. Steigner, Viviany R. Taqueti, Hicham Skali, Ron Blankstein, Marcelo F. Di Carli, Sharmila Dorbala. Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CTRadiology 2019; 291(2): 330 doi: 10.1148/radiol.2019181793
37
Kalliopi Pafili, Efstratios Maltezos, Nikolaos Papanas. Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetesExpert Opinion on Drug Metabolism & Toxicology 2016; 12(11): 1367 doi: 10.1080/17425255.2016.1229302
38
Manuela Abbate, Catalina M. Mascaró, Sofía Montemayor, Miguel Casares, Cristina Gómez, Lucia Ugarriza, Silvia Tejada, Itziar Abete, Maria Angeles Zulet, Antoni Sureda, J. Alfredo Martínez, Josep A. Tur. Non-Alcoholic Fatty Liver Disease Is Associated with Kidney Glomerular Hyperfiltration in Adults with Metabolic SyndromeJournal of Clinical Medicine 2021; 10(8): 1717 doi: 10.3390/jcm10081717
39
Jelena Stevanović, Jorge Beleza, Pedro Coxito, António Ascensão, José Magalhães. Physical exercise and liver “fitness”: Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver diseaseMolecular Metabolism 2020; 32: 1 doi: 10.1016/j.molmet.2019.11.015
40
Mustafa Koplay, Mustafa Gok, Mesut Sivri. The association between coronary artery disease and nonalcoholic fatty liver disease and noninvasive imaging methodsElectronic Journal of General Medicine 2019; 16(6): em165 doi: 10.29333/ejgm/110689
41
Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugsJournal of Diabetes and its Complications 2017; 31(3): 521 doi: 10.1016/j.jdiacomp.2016.12.006
42
Niki Katsiki, George Dimitriadis, Dimitri P. Mikhailidis. Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection?Angiology 2019; 70(7): 581 doi: 10.1177/0003319719848204
43
Yu. M. Kazakov, Yu. I. Manusha, T. A. Trybrat, N. I. Chekalina, ’ S. V. Shut’. THE CLINICAL AND BIOCHEMICAL FEATURES OF LIVER‎’‎ FUNCTIONAL STATE IN PATIENTS WITH ISCHEMIC HEART DISEASE IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE Bulletin of Problems Biology and Medicine 2019; 3(152): 118 doi: 10.29254/2077-4214-2019-3-152-118-121
44
TI Ledovskaya, ME Statsenko, SV Turkina, TA Konyakhina, KS Yusupov, EE Gorbacheva. Cardiovascular comorbidity in patients with nonalcoholic fatty liver diseaseMedicine of Extreme Situations 2021; (2021(4)) doi: 10.47183/mes.2021.045
45
Niki Katsiki, Francesco Purrello, Costas Tsioufis, Dimitri P. Mikhailidis. Cardiovascular disease prevention strategies for type 2 diabetes mellitusExpert Opinion on Pharmacotherapy 2017; 18(12): 1243 doi: 10.1080/14656566.2017.1351946
46
A Systematic Review of NAFLD-Associated Extrahepatic Disorders in YouthsJournal of Clinical Medicine 2019; 8(6): 868 doi: 10.3390/jcm8060868
47
Cristiane Villela-Nogueira, Nathalie Leite, Claudia Cardoso, Gil Salles. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms?International Journal of Molecular Sciences 2016; 17(4): 460 doi: 10.3390/ijms17040460
48
Genovefa D. Kolovou, Gerald F. Watts, Dimitri P. Mikhailidis, Pablo Pérez-Martínez, Samia Mora, Helen Bilianou, George Panotopoulos, Niki Katsiki, Teik C. Ooi, José Lopez-Miranda, Anne Tybjærg-Hansen, Nicholas Tentolouris, Børge G. Nordestgaard. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main TextCurrent Vascular Pharmacology 2019; 17(5): 498 doi: 10.2174/1570161117666190507110519
49
Theodora Griva, Chrysoula Boutari, Konstantinos Tziomalos, Michael Doumas, Asterios Karagiannis, Vasilios G. Athyros. Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?The Open Hypertension Journal 2017; 9(1): 1 doi: 10.2174/1876526201709010001
50
Niki Katsiki, Dimitri P Mikhailidis, Maciej Banach. Leptin, cardiovascular diseases and type 2 diabetes mellitusActa Pharmacologica Sinica 2018; 39(7): 1176 doi: 10.1038/aps.2018.40
51
Rosaria Vincenza Giglio, Angelo Maria Patti, Dragana Nikolic, Giovanni Li Volti, Khalid Al-Rasadi, Niki Katsiki, Dimitri P. Mikhailidis, Giuseppe Montalto, Ekaterina Ivanova, Alexander N. Orekhov, Manfredi Rizzo. The effect of bergamot on dyslipidemiaPhytomedicine 2016; 23(11): 1175 doi: 10.1016/j.phymed.2015.12.005
52
Arinc Ozturk, Ramin Mohammadi, Theodore T. Pierce, Sagar Kamarthi, Manish Dhyani, Joseph R. Grajo, Kathleen E. Corey, Raymond T. Chung, Atul K. Bhan, Jagpreet Chhatwal, Anthony E. Samir. Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver DiseaseUltrasound in Medicine & Biology 2020; 46(4): 972 doi: 10.1016/j.ultrasmedbio.2019.12.020
53
Niki Katsiki, Vasilios G Athyros. Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatmentCurrent Medical Research and Opinion 2019; 35(7): 1305 doi: 10.1080/03007995.2019.1589152
54
Niki Katsiki, Ele Ferrannini, Christos Mantzoros. New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspectiveMetabolism 2020; 107: 154218 doi: 10.1016/j.metabol.2020.154218
55
Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis. Cardiovascular effects of sodium–glucose cotransporter 2 inhibitors: multiple actionsCurrent Medical Research and Opinion 2016; 32(9): 1513 doi: 10.1080/03007995.2016.1201465
56
Erenius Toppo, S. Sylvester Darvin, S. Esakkimuthu, A. Stalin, K. Balakrishna, K. Sivasankaran, P. Pandikumar, S. Ignacimuthu, N.A. Al-Dhabi. Antihyperlipidemic and hepatoprotective effects of Gardenin A in cellular and high fat diet fed rodent modelsChemico-Biological Interactions 2017; 269: 9 doi: 10.1016/j.cbi.2017.03.013
57
Lucia Pacifico, Enea Bonci, Gian Andreoli, Michele Di Martino, Alessia Gallozzi, Ester De Luca, Claudio Chiesa. The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/ObesityInternational Journal of Molecular Sciences 2016; 17(8): 1218 doi: 10.3390/ijms17081218
58
Yu-Tao Zhan, Hai-Ying Su, Wei An. Glycosyltransferases and non-alcoholic fatty liver diseaseWorld Journal of Gastroenterology 2016; 22(8): 2483-2493 doi: 10.3748/wjg.v22.i8.2483
59
Niki Katsiki, Michael Doumas, Vasilios Athyros. Metabolic syndrome: joint diagnostic criteria and links with comorbiditiesHormones 2019; 18(1): 107 doi: 10.1007/s42000-018-0074-9
60
Helena Katchman, Shira Zelber-Sagi, Roni Baruch, Galia Berman, Idit F. Schwartz, Doron Schwartz, Richard Nakache, Yaacov Goykhman, Polina Katz, Oren Shibolet, Moshe Shashar, Ayelet Grupper. Progression and new onset of nonalcoholic fatty liver disease in living kidney donors compared to healthy controlsClinical Transplantation 2018; 32(5): e13240 doi: 10.1111/ctr.13240
61
Kalliopi Pafili, Manfredi Rizzo, Nikolaos Papanas. New antihyperglycaemic agents and cardiovascular diseaseCurrent Opinion in Cardiology 2018; 33(4): 444 doi: 10.1097/HCO.0000000000000524
62
Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Manfredi Rizzo, Ali A. Rizvi. Future perspectives of the pharmacological management of diabetic dyslipidemiaExpert Review of Clinical Pharmacology 2019; 12(2): 129 doi: 10.1080/17512433.2019.1567328
63
Pakkapon Rattanachaisit, Paweena Susantitaphong, Kessarin Thanapirom, Roongruedee Chaiteerakij, Piyawat Komolmit, Pisit Tangkijvanich, Sombat Treeprasertsuk. Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysisAsian Biomedicine 2018; 12(1): 3 doi: 10.1515/abm-2018-0026
64
Mohsen Mazidi, Niki Katsiki, Dimitri P. Mikhailidis, Maciej Banach. Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver DiseaseJournal of the American College of Nutrition 2019; 38(7): 633 doi: 10.1080/07315724.2018.1507011
65
Mayur Virarkar, Janio Szklaruk, Corey T. Jensen, Melissa W. Taggart, Priya Bhosale. What's New in Hepatic SteatosisSeminars in Ultrasound, CT and MRI 2021; 42(4): 405 doi: 10.1053/j.sult.2021.03.001
66
Laura J. Brattain, Brian A. Telfer, Manish Dhyani, Joseph R. Grajo, Anthony E. Samir. Objective Liver Fibrosis Estimation from Shear Wave Elastography2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2018; : 1 doi: 10.1109/EMBC.2018.8513011
67
Morgan Marcuccilli, Michel Chonchol. NAFLD and Chronic Kidney DiseaseInternational Journal of Molecular Sciences 2016; 17(4): 562 doi: 10.3390/ijms17040562
68
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!Metabolism 2019; 101: 154001 doi: 10.1016/j.metabol.2019.154001
69
Jake P. Mann, Paul Carter, Matthew J. Armstrong, Hesham K. Abdelaziz, Hardeep Uppal, Billal Patel, Suresh Chandran, Ranjit More, Philip N. Newsome, Rahul Potluri, Michael W. Greene. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factorsPLOS ONE 2020; 15(10): e0241357 doi: 10.1371/journal.pone.0241357
70
Niki Katsiki, Christos Mantzoros. Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis)Metabolism 2021; 114: 154333 doi: 10.1016/j.metabol.2020.154333
71
Daniel A Giles, Maria E Moreno-Fernandez, Traci E Stankiewicz, Simon Graspeuntner, Monica Cappelletti, David Wu, Rajib Mukherjee, Calvin C Chan, Matthew J Lawson, Jared Klarquist, Annika Sünderhauf, Samir Softic, C Ronald Kahn, Kerstin Stemmer, Yoichiro Iwakura, Bruce J Aronow, Rebekah Karns, Kris A Steinbrecher, Christopher L Karp, Rachel Sheridan, Shiva K Shanmukhappa, Damien Reynaud, David B Haslam, Christian Sina, Jan Rupp, Simon P Hogan, Senad Divanovic. Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modelingNature Medicine 2017; 23(7): 829 doi: 10.1038/nm.4346
72
Mengzhen Dong, Shousheng Liu, Mengke Wang, Yifen Wang, Yongning Xin, Shiying Xuan. Relationship between AGT rs2493132 polymorphism and the risk of coronary artery disease in patients with NAFLD in the Chinese Han populationJournal of International Medical Research 2021; 49(7): 030006052110192 doi: 10.1177/03000605211019263
73
Lars H. Breimer, Dimitri P. Mikhailidis. Does bilirubin protect against developing diabetes mellitus?Journal of Diabetes and its Complications 2016; 30(4): 728 doi: 10.1016/j.jdiacomp.2016.01.019
74
Yun Kyung Cho, Yu Mi Kang, Jee Hee Yoo, Jiwoo Lee, Seung Eun Lee, Dong Hyun Yang, Joon-Won Kang, Joong-Yeol Park, Chang Hee Jung, Hong-Kyu Kim, Woo Je Lee. The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcificationScientific Reports 2018; 8(1) doi: 10.1038/s41598-018-30465-y
75
Niki Katsiki, Genovefa Kolovou, Pablo Perez-Martinez, Dimitri P. Mikhailidis. Dyslipidaemia in the elderly: to treat or not to treat?Expert Review of Clinical Pharmacology 2018; 11(3): 259 doi: 10.1080/17512433.2018.1425138
76
Xin-yan Yu, Xiao-xiao Song, Yu-ling Tong, Ling-yan Wu, Zhen-ya Song. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in ChinaMedicine 2020; 99(48): e23360 doi: 10.1097/MD.0000000000023360
77
Kívia de Andrade, Fabiana Moura, John dos Santos, Orlando de Araújo, Juliana de Farias Santos, Marília Goulart. Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-AcetylcysteineInternational Journal of Molecular Sciences 2015; 16(12): 30269 doi: 10.3390/ijms161226225
78
Georgios A. Christou, Niki Katsiki, John Blundell, Gema Fruhbeck, Dimitrios N. Kiortsis. Semaglutide as a promising antiobesity drugObesity Reviews 2019; 20(6): 805 doi: 10.1111/obr.12839
79
Niki Katsiki, Dimitri P Mikhailidis, Maciej Banach. Lipid-lowering agents for concurrent cardiovascular and chronic kidney diseaseExpert Opinion on Pharmacotherapy 2019; 20(16): 2007 doi: 10.1080/14656566.2019.1649394
80
Rajkumar Chinnadurai, James Ritchie, Darren Green, Philip A Kalra. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney diseaseNephrology Dialysis Transplantation 2019; 34(3): 449 doi: 10.1093/ndt/gfx381
81
Karolina Grąt, Michał Grąt, Olgierd Rowiński. Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver DiseaseBiomedicines 2020; 8(9): 298 doi: 10.3390/biomedicines8090298
82
Manca Povsic, On Yee Wong, Richard Perry, Juliana Bottomley. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)Advances in Therapy 2019; 36(7): 1574 doi: 10.1007/s12325-019-00960-3
83
Binayak Sinha, Debasis Datta, Samit Ghosal. Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetesJGH Open 2021; 5(2): 219 doi: 10.1002/jgh3.12473
84
Tae Woo Jung, Hye Jin Yoo, Kyung Mook Choi. Implication of hepatokines in metabolic disorders and cardiovascular diseasesBBA Clinical 2016; 5: 108 doi: 10.1016/j.bbacli.2016.03.002
85
Niki Katsiki, Dimitri P Mikhailidis. Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trialJournal of Diabetes and its Complications 2017; 31(1): 1 doi: 10.1016/j.jdiacomp.2016.09.005
86
Jonathan M. Hazlehurst, Conor Woods, Thomas Marjot, Jeremy F. Cobbold, Jeremy W. Tomlinson. Non-alcoholic fatty liver disease and diabetesMetabolism 2016; 65(8): 1096 doi: 10.1016/j.metabol.2016.01.001
87
Arrigo F G Cicero, Alessandro Colletti, Gani Bajraktari, Olivier Descamps, Dragan M Djuric, Marat Ezhov, Zlatko Fras, Niki Katsiki, Michel Langlois, Gustavs Latkovskis, Demosthenes B Panagiotakos, Gyorgy Paragh, Dimitri P Mikhailidis, Olena Mitchenko, Bernhard Paulweber, Daniel Pella, Christos Pitsavos, Željko Reiner, Kausik K Ray, Manfredi Rizzo, Amirhossein Sahebkar, Maria-Corina Serban, Laurence S Sperling, Peter P Toth, Dragos Vinereanu, Michal Vrablík, Nathan D Wong, Maciej Banach. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert PanelNutrition Reviews 2017; 75(9): 731 doi: 10.1093/nutrit/nux047
88
Niki Katsiki, Panagiotis Anagnostis, Kalliopi Kotsa, Dimitrios G. Goulis, Dimitri P. Mikhailidis. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitusCurrent Pharmaceutical Design 2019; 25(18): 2051 doi: 10.2174/1381612825666190708192134
89
Mohamad Kareem Marrache, Don C. Rockey. Statins for treatment of chronic liver diseaseCurrent Opinion in Gastroenterology 2021; 37(3): 200 doi: 10.1097/MOG.0000000000000716